Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Aminophenazone→

Aminophenazone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
58-15-1
Molecular formula
C13H17N3O
Molecular weight
231.29 g/mol
Drug class
Pyrazolone analgesic and antipyretic (aminopyrine)historical agent
Mechanism of action
Inhibits cyclo-oxygenase-mediated prostaglandin synthesis, producing analgesic and antipyretic effects. Use was substantially restricted or discontinued in many countries because of serious blood dyscrasias, particularly agranulocytosis.
Indications / reported uses
  • Historical treatment of pain and fever. Aminophenazone/aminopyrine is withdrawn or restricted in many jurisdictions due to agranulocytosis risk and should not be presented as a routine current analgesic.

Sources: NLM MeSH — Aminophenazone · PubMed — Aminopyrine agranulocytosis safety · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Aminophenazone Environmental Risk Assessment (ERA) (the Aminophenazone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.